Key result
This editorial introduces a study assessing the clinical significance of baseline plasma MMP-9 levels in predicting two-year adverse cardiovascular events in STEMI patients undergoing primary PCI.
Why the study?
Do baseline plasma MMP-9 levels predict two-year adverse cardiovascular events in patients who underwent primary PCI after STEMI?
Do baseline plasma MMP-9 levels predict two-year adverse cardiovascular events in patients who underwent primary PCI after STEMI?
This editorial discusses a study evaluating the prognostic utility of baseline MMP-9 levels for predicting adverse cardiovascular events in STEMI patients undergoing primary PCI.
Patients with acute coronary syndromes are a heterogeneous population, with different levels of severity and various predictors of mortality.Due to interactions between the various risk factors, scores have been created in order to identify populations at greater risk.1,2 In addition to clinical markers, biochemical markers such as elevated troponin T and C-reactive protein levels are strongly related to the long-term risk of death from cardiac causes.3 Matrix metalloproteinases (MMPs) are enzymes involved in extracellular matrix remodeling and leukocyte recruitment to sites of inflammation, and act as important inflammatory modulators.MMP-9 plays a key role in the progression of atherosclerosis and vulnerability to plaque rupture, 4 and its plasma levels increase in patients with acute myocardial infarction.However, available data on the specific impact of baseline plasma MMP-9 levels and their utility as a prognostic marker in coronary artery disease are limited and at times conflicting.5,6 In this issue of the Journal, Somuncu et al. 7 present a study aiming to assess the clinical significance of MMP-9 in predicting two-year adverse cardiovascular events in patients who underwent primary percutaneous coronary intervention (PCI) after ST-elevation myocardial infarction (STEMI).
No takes yet. Share an insight, caveat, or question.
Jorge Mimoso (2020) conducted an editorial in ST-elevation myocardial infarction (STEMI). Baseline plasma MMP-9 levels was evaluated on Two-year adverse cardiovascular events. This editorial introduces a study assessing the clinical significance of baseline plasma MMP-9 levels in predicting two-year adverse cardiovascular events in STEMI patients undergoing primary PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: